GlassScriptPhysician profile
Aaron L Mills
NPI 1275628349
$3,869.82
in general payments reported to CMS, 2019-2025
31 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $69.80 · 2021: $463 · 2022: $804 · 2023: $878 · 2024: $819 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.54 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $586.92 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $521.84 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $310.24 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $297.11 | 2021-2025 | Freestyle Libre |
| Pfizer INC. | $235.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.62 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $160.64 | 2019-2025 | Rexulti, Abilify Maintena |
| Daiichi Sankyo INC. | $143.04 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $120.38 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $107.80 | 2019-2024 | Vaxneuvance, Gardasil, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $74.23 | 2022-2023 | Eliquis |
| Neurocrine Biosciences, INC. | $70.33 | 2022-2024 | Ingrezza |
| Dexcom, INC. | $43.02 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $41.75 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.81 | 2024 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $35.91 | 2020-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $35.06 | 2022 | |
| Eisai INC. | $34.43 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $27.83 | 2025 | Monoferric |
| Gilead Sciences, INC. | $22.29 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.80 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.17 | 2025 | Caplyta |
| Mylan Specialty L.P. | $16.89 | 2024 | Yupelri |
| Medtronic, INC. | $16.30 | 2021 | |
| Abbvie INC. | $16.12 | 2021 | |
| Lundbeck LLC | $15.66 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.23 | 2021 | |
| Exact Sciences Corporation | $14.93 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.58 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.